These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 32323895)

  • 121. Effective Radiosensitization of HNSCC Cell Lines by DNA-PKcs Inhibitor AZD7648 and PARP Inhibitors Talazoparib and Niraparib.
    Mentzel J; Hildebrand LS; Kuhlmann L; Fietkau R; Distel LV
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891817
    [TBL] [Abstract][Full Text] [Related]  

  • 122. Targeting DNA damage response in head and neck cancers through abrogation of cell cycle checkpoints.
    Molkentine JM; Molkentine DP; Bridges KA; Xie T; Yang L; Sheth A; Heffernan TP; Clump DA; Faust AZ; Ferris RL; Myers JN; Frederick MJ; Mason KA; Meyn RE; Pickering CR; Skinner HD
    Int J Radiat Biol; 2021; 97(8):1121-1128. PubMed ID: 32073931
    [TBL] [Abstract][Full Text] [Related]  

  • 123. Niraparib (MK-4827), a novel poly(ADP-Ribose) polymerase inhibitor, radiosensitizes human lung and breast cancer cells.
    Bridges KA; Toniatti C; Buser CA; Liu H; Buchholz TA; Meyn RE
    Oncotarget; 2014 Jul; 5(13):5076-86. PubMed ID: 24970803
    [TBL] [Abstract][Full Text] [Related]  

  • 124. PARP inhibitor niraparib as a radiosensitizer promotes antitumor immunity of radiotherapy in EGFR-mutated non-small cell lung cancer.
    Zhang N; Gao Y; Zeng Z; Luo Y; Jiang X; Zhang J; Li J; Zhang J; Gong Y; Xie C
    Clin Transl Oncol; 2021 Sep; 23(9):1827-1837. PubMed ID: 33774805
    [TBL] [Abstract][Full Text] [Related]  

  • 125. Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma.
    Chornenkyy Y; Agnihotri S; Yu M; Buczkowicz P; Rakopoulos P; Golbourn B; Garzia L; Siddaway R; Leung S; Rutka JT; Taylor MD; Dirks PB; Hawkins C
    Mol Cancer Ther; 2015 Nov; 14(11):2560-8. PubMed ID: 26351319
    [TBL] [Abstract][Full Text] [Related]  

  • 126. Niraparib for the treatment of ovarian cancer.
    Essel KG; Moore KN
    Expert Rev Anticancer Ther; 2018 Aug; 18(8):727-733. PubMed ID: 29911447
    [TBL] [Abstract][Full Text] [Related]  

  • 127. The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities.
    Moore KN; Mirza MR; Matulonis UA
    Gynecol Oncol; 2018 Apr; 149(1):214-220. PubMed ID: 29397193
    [TBL] [Abstract][Full Text] [Related]  

  • 128. Niraparib: A Review in Ovarian Cancer.
    Heo YA; Duggan ST
    Target Oncol; 2018 Aug; 13(4):533-539. PubMed ID: 30073633
    [TBL] [Abstract][Full Text] [Related]  

  • 129. Systematic review and meta-analysis of radiotherapy in various head and neck cancers: comparing photons, carbon-ions and protons.
    Ramaekers BL; Pijls-Johannesma M; Joore MA; van den Ende P; Langendijk JA; Lambin P; Kessels AG; Grutters JP
    Cancer Treat Rev; 2011 May; 37(3):185-201. PubMed ID: 20817407
    [TBL] [Abstract][Full Text] [Related]  

  • 130. Niraparib for the treatment of ovarian cancer.
    Kanjanapan Y; Lheureux S; Oza AM
    Expert Opin Pharmacother; 2017 Apr; 18(6):631-640. PubMed ID: 28299955
    [TBL] [Abstract][Full Text] [Related]  

  • 131. Niraparib for the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
    Kerliu L; Myruski S; Bhatti A; Soni P; Petrosius P; Pervanas HC; Horton ER
    Ann Pharmacother; 2020 Oct; 54(10):1010-1015. PubMed ID: 32172572
    [TBL] [Abstract][Full Text] [Related]  

  • 132. [Cancer therapy by PARP inhibitors].
    Seimiya H
    Nihon Rinsho; 2015 Aug; 73(8):1330-5. PubMed ID: 26281686
    [TBL] [Abstract][Full Text] [Related]  

  • 133. Photon- and Proton-Mediated Biological Effects: What Has Been Learned?
    Jumaniyazova E; Smyk D; Vishnyakova P; Fatkhudinov T; Gordon K
    Life (Basel); 2022 Dec; 13(1):. PubMed ID: 36675979
    [TBL] [Abstract][Full Text] [Related]  

  • 134. Proton Therapy for Squamous Cell Carcinoma of the Head and Neck: Early Clinical Experience and Current Challenges.
    Nuyts S; Bollen H; Ng SP; Corry J; Eisbruch A; Mendenhall WM; Smee R; Strojan P; Ng WT; Ferlito A
    Cancers (Basel); 2022 May; 14(11):. PubMed ID: 35681568
    [TBL] [Abstract][Full Text] [Related]  

  • 135. Niraparib for ovarian cancer.
    Aust Prescr; 2021 Dec; 44(6):208-209. PubMed ID: 35002037
    [No Abstract]   [Full Text] [Related]  

  • 136. Proton and photon radiosensitization effects of niraparib, a PARP-1/-2 inhibitor, on human head and neck cancer cells.
    Wang L; Cao J; Wang X; Lin E; Wang Z; Li Y; Li Y; Chen M; Wang X; Jiang B; Zhang R; Sahoo N; Zhang X; Zhu XR; Myers JN; Frank SJ
    Head Neck; 2020 Sep; 42(9):2244-2256. PubMed ID: 32323895
    [TBL] [Abstract][Full Text] [Related]  

  • 137.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 138.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 139.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 140.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.